Biomedical
Rebecca Strawbridge,
Nefize Yalin,
Stelios Orfanos,
Allan H. Young
Peer Reviewed
The article "Acetazolamide for Bipolar Disorders: A Scoping Review" examines the potential of acetazolamide, a carbonic anhydrase inhibitor, as a treatment for bipolar disorder. The review synthesizes available evidence on its effects, acceptability, tolerability, and intervention characteristics, such as dosage and duration. The authors highlight the need for further research to determine the viability of acetazolamide as a treatment option for bipolar disorders.
The review explores the possibility of acetazolamide benefiting individuals with bipolar disorder, noting that current evidence is preliminary and further research is needed to establish its efficacy.
The review assesses the acceptability and tolerability of acetazolamide, indicating that while some studies report positive outcomes, the evidence is not yet robust enough to draw definitive conclusions.
The review examines intervention characteristics, including dosage and duration, but emphasizes the need for standardized protocols and further studies to determine optimal treatment parameters.
Show by month | Manuscript | Video Summary |
---|---|---|
2025 May | 1 | 1 |
2025 April | 84 | 84 |
2025 March | 75 | 75 |
2025 February | 55 | 55 |
2025 January | 56 | 56 |
2024 December | 59 | 59 |
2024 November | 50 | 50 |
Total | 380 | 380 |
Show by month | Manuscript | Video Summary |
---|---|---|
2025 May | 1 | 1 |
2025 April | 84 | 84 |
2025 March | 75 | 75 |
2025 February | 55 | 55 |
2025 January | 56 | 56 |
2024 December | 59 | 59 |
2024 November | 50 | 50 |
Total | 380 | 380 |